Julie Teruya-Feldstein
Overview
Explore the profile of Julie Teruya-Feldstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
13052
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barley K, Parekh A, Salam S, Mendu D, Shukla R, Vatti D, et al.
Blood Adv
. 2024 Jan;
8(7):1634-1638.
PMID: 38285963
No abstract available.
2.
Bantilan K, Smith A, Maurer M, Teruya-Feldstein J, Matasar M, Moskowitz A, et al.
Blood Adv
. 2024 Jan;
8(9):2172-2181.
PMID: 38271621
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard-of-care for patients with advanced-stage diffuse large B-cell lymphoma (DLBCL), despite findings that patients with nongerminal center B-cell like (non-GCB)...
3.
Morganti C, Ito K, Yanase C, Verma A, Teruya-Feldstein J, Ito K
EMBO Rep
. 2022 Mar;
23(5):e54262.
PMID: 35229971
Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis with morphologic dysplasia and a propensity to transform into overt acute myeloid leukemia (AML). Our analysis of two cohorts of 20 MDS...
4.
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al.
Nat Med
. 2021 Dec;
27(12):2099-2103.
PMID: 34893771
B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric antigen receptor (CAR)-T cell therapy in multiple myeloma (MM). Here, we describe the case of a patient with MM...
5.
Wheeler E, Vora S, Mayer D, Kotini A, Olszewska M, Park S, et al.
Cancer Discov
. 2021 Oct;
12(3):836-855.
PMID: 34620690
Significance: SF mutations are disease-defining in MDS, but their critical effectors remain unknown. We discover the first direct target of convergent missplicing by mutant U2AF1 and SRSF2, a long GNAS...
6.
Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, et al.
Proc Natl Acad Sci U S A
. 2021 May;
118(22).
PMID: 34050029
Fifty percent of diffuse large B cell lymphoma (DLBCL) cases lack cell-surface expression of the class I major histocompatibility complex (MHC-I), thus escaping recognition by cytotoxic T cells. Here we...
7.
Zhan Y, Ward S, Fiel M, Teruya-Feldstein J, McKay E, Dekio F
Liver Int
. 2021 Mar;
41(9):2132-2138.
PMID: 33786975
Background & Aims: Tufting enteropathy (TE) is a rare congenital disorder often caused by mutations in the gene encoding epithelial cell adhesion molecule (EpCam). The disease leads to diarrhoea, intestinal...
8.
White K, Qualtieri J, Courville E, Beck R, Alobeid B, Czuchlewski D, et al.
Acad Pathol
. 2021 Mar;
8:2374289521990823.
PMID: 33644302
Hematopathology fellowship education has grown in complexity as patient-centered treatment plans have come to depend on integration of clinical, morphologic, immunophenotypic, molecular, and cytogenetic variables. This complexity is in competition...
9.
Goel A, Filimonov A, Teruya-Feldstein J, Salib C, Rousso J, Hackett A, et al.
Am J Otolaryngol
. 2021 Feb;
42(4):102977.
PMID: 33636684
Objective: To describe a case of Burkitt lymphoma (BL) in a child manifesting with acute airway obstruction. To review available literature on the clinical features and characteristic presentation of this...
10.
El Jamal S, Salib C, Stock A, Uriarte-Haparnas N, Glicksberg B, Teruya-Feldstein J, et al.
Pathol Res Pract
. 2020 Aug;
216(9):153063.
PMID: 32825937
No abstract available.